Source:http://linkedlifedata.com/resource/pubmed/id/12070007
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2002-6-18
|
| pubmed:abstractText |
Results of previous studies have suggested that transplantation-related mortality among patients with chronic graft-versus-host disease (GVHD) may be reduced by combined treatment with cyclosporine (CSP) and prednisone rather than by prednisone alone. In a randomized trial, we assessed the efficacy of cyclosporine plus prednisone versus prednisone alone as initial therapy for chronic GHVD among patients whose platelet counts were higher than 100,000/microL. Prednisone was administered initially at a dose of 1.0 mg/kg per day orally, followed by a prolonged taper, and cyclosporine was administered at 6 mg/kg orally twice daily every other day. The cumulative incidence of transplantation-related mortality at 5 years from enrollment was 17% (95% CI, 0.11-0.23) in the CSP plus prednisone arm and 13% (95% CI, 0.08-0.19) in the prednisone arm. The hazards of transplantation-related mortality, overall mortality, recurrent malignancy, secondary therapy, and discontinuation of all immunosuppressive therapy were not significantly different between the 2 arms, but survival without recurrent malignancy was lower in the 2-drug arm (P =.03). Avascular necrosis developed in 18 (13%) of the 142 patients in the CSP plus prednisone arm and in 32 (22%) of the 145 patients in the prednisone arm (P =.04). Treatment with CSP plus prednisone may reduce the risk for steroid-related toxicity, but results of the current study do not substantiate the hypothesis that the administration of CSP reduces transplantation-related mortality among patients with chronic GVHD.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0006-4971
|
| pubmed:author |
pubmed-author:AnasettiClaudioC,
pubmed-author:AppelbaumFrederick RFR,
pubmed-author:DeegH JoachimHJ,
pubmed-author:FlowersMary E DME,
pubmed-author:KocSibelS,
pubmed-author:LeisenringWendyW,
pubmed-author:MartinPaul JPJ,
pubmed-author:NashRichard ARA,
pubmed-author:SandersJean EJE,
pubmed-author:StorbRainerR,
pubmed-author:WitherspoonRobert PRP
|
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
100
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
48-51
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:12070007-Adolescent,
pubmed-meshheading:12070007-Adult,
pubmed-meshheading:12070007-Child,
pubmed-meshheading:12070007-Child, Preschool,
pubmed-meshheading:12070007-Chronic Disease,
pubmed-meshheading:12070007-Cyclosporine,
pubmed-meshheading:12070007-Drug Administration Schedule,
pubmed-meshheading:12070007-Drug Therapy, Combination,
pubmed-meshheading:12070007-Female,
pubmed-meshheading:12070007-Graft vs Host Disease,
pubmed-meshheading:12070007-Hematologic Diseases,
pubmed-meshheading:12070007-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:12070007-Humans,
pubmed-meshheading:12070007-Immunosuppressive Agents,
pubmed-meshheading:12070007-Male,
pubmed-meshheading:12070007-Middle Aged,
pubmed-meshheading:12070007-Prednisone,
pubmed-meshheading:12070007-Survival Analysis,
pubmed-meshheading:12070007-Thrombocytopenia,
pubmed-meshheading:12070007-Transplantation, Homologous
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone.
|
| pubmed:affiliation |
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial
|